Envestnet Asset Management Inc. decreased its holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 16.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 241,380 shares of the biopharmaceutical company’s stock after selling 48,097 shares during the period. Envestnet Asset Management Inc. owned about 0.11% of Horizon Therapeutics Public worth $14,939,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. Advisors Asset Management Inc. increased its position in shares of Horizon Therapeutics Public by 17.2% during the third quarter. Advisors Asset Management Inc. now owns 3,244 shares of the biopharmaceutical company’s stock worth $201,000 after purchasing an additional 477 shares in the last quarter. Bank of Montreal Can increased its position in shares of Horizon Therapeutics Public by 1.5% during the third quarter. Bank of Montreal Can now owns 859,802 shares of the biopharmaceutical company’s stock worth $55,044,000 after purchasing an additional 12,724 shares in the last quarter. Centiva Capital LP acquired a new position in shares of Horizon Therapeutics Public during the second quarter worth $734,000. Strs Ohio increased its position in shares of Horizon Therapeutics Public by 0.8% during the third quarter. Strs Ohio now owns 715,500 shares of the biopharmaceutical company’s stock worth $44,282,000 after purchasing an additional 5,994 shares in the last quarter. Finally, Korea Investment CORP increased its position in shares of Horizon Therapeutics Public by 94.8% during the third quarter. Korea Investment CORP now owns 118,513 shares of the biopharmaceutical company’s stock worth $7,335,000 after purchasing an additional 57,678 shares in the last quarter. Institutional investors own 91.01% of the company’s stock.
Insider Transactions at Horizon Therapeutics Public
In other news, EVP Andy Pasternak sold 27,129 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $113.03, for a total transaction of $3,066,390.87. Following the sale, the executive vice president now directly owns 56,338 shares of the company’s stock, valued at approximately $6,367,884.14. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CFO Aaron Cox sold 36,148 shares of the stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $113.17, for a total transaction of $4,090,869.16. Following the sale, the chief financial officer now directly owns 277 shares of the company’s stock, valued at approximately $31,348.09. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Andy Pasternak sold 27,129 shares of the stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $113.03, for a total transaction of $3,066,390.87. Following the sale, the executive vice president now directly owns 56,338 shares in the company, valued at $6,367,884.14. The disclosure for this sale can be found here. Insiders have sold a total of 100,184 shares of company stock valued at $11,285,478 in the last ninety days. 2.50% of the stock is currently owned by corporate insiders.
Horizon Therapeutics Public Price Performance
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on HZNP shares. Guggenheim downgraded Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and upped their price target for the stock from $98.00 to $116.50 in a research report on Tuesday, December 13th. StockNews.com raised shares of Horizon Therapeutics Public from a “hold” rating to a “buy” rating in a report on Thursday, November 3rd. BMO Capital Markets lowered shares of Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 13th. HC Wainwright began coverage on shares of Horizon Therapeutics Public in a report on Tuesday, November 1st. They set a “neutral” rating and a $74.00 price objective on the stock. Finally, Wells Fargo & Company lowered shares of Horizon Therapeutics Public from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $118.00 to $116.50 in a report on Monday, December 12th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Horizon Therapeutics Public has an average rating of “Hold” and an average price target of $111.42.
Horizon Therapeutics Public Profile
Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.
Featured Stories
- Get a free copy of the StockNews.com research report on Horizon Therapeutics Public (HZNP)
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
- Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating).
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.
